Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar:183:103919.
doi: 10.1016/j.critrevonc.2023.103919. Epub 2023 Feb 1.

Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review

Mees D Egeler  1 , Marieke van Leeuwen  2 , Itske Fraterman  2 , Noelle M J van den Heuvel  2 , Annelies H Boekhout  2 , Julia Lai-Kwon  3 , Erica A Wilthagen  4 , Hanna Eriksson  5 , John B Haanen  6 , Sofie Wilgenhof  6 , Paolo A Ascierto  7 , Alexander C J van Akkooi  8 , Lonneke V van de Poll-Franse  9
Affiliations

Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review

Mees D Egeler et al. Crit Rev Oncol Hematol. 2023 Mar.

Abstract

Introduction: This systematic scoping review compares the toxicities experienced by patients receiving immune checkpoint inhibitors (ICIs) or targeted therapy (TT) for stage III (resected and unresectable) and stage IV melanoma.

Methods: OVID Medline, Embase, and PsycInfo were searched to identify Phase III trials reporting toxicities of FDA-approved ICIs and TT for advanced melanoma. AEs that were reported by ≥ 10% of patients in the evaluated trials were included.

Results: Toxicity profiles of 11208 patients from 24 studies were reviewed. The rate of AEs was lower with ICIs compared to TT. However, ICIs were associated with higher rates of long-term or permanent AEs compared to TT, where toxicities generally were shortterm and reversible with treatment discontinuation.

Conclusion: The toxicity profiles of ICIs and TT vary substantially. Whilst the rate of AEs was lower with ICIs than during TT, it was also associated with higher rates of potentially chronic AEs.

Keywords: Adverse events; Immune Checkpoint Inhibitors; Melanoma; Targeted therapy; Toxicities.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement M D Egeler: received a research grant from the EORTC Quality of Life Group for this review. H Eriksson: Pierre Febre Nordic, BmS Merck and Novartis (advisory board) and received researchgrants from SkyLine Dx. J B Haanen: Achilles Therapeutics, AstraZeneca, Bristol Myers Squibb, BioNTech, Immunocore,Ipsen, Instil Bio, Iovance Bio, MSD, Merck Serono, Molecular Partners, Novartis, NeogeneTherapeutics, Pfizer, Roche/Genentech, Sanofi and T-Knife (advisory board), has received researchgrants from Asher Bio, Amgen, Bristol Myers Squibb, MSD, BioNTech, Neogene Therapeutics andNovartis, has stock options in Neogene therapeutics, and is the current Editor-in-Chief of ESMOImmuno-Oncology and Technology S.T. has received speaker’s fees from AstraZeneca, Ipsen,Novartis and Roche, and is listed on the following patents: Indel mutations as a therapeutic target and predictive biomarker (PCTGB2018/051892 and PCTGB2018/051893, as inventor) and Clear CellRenal Cell Carcinoma Biomarkers (P113326GB, as co-inventor). S Wilgenhof: Eisai, Bristol-Myers Squibb and Pierre Fabre (advisory role, all paid to institution).P A Ascierto: Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC,Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health, ValoTX, Replimmune (consultingand advisory board), received research grants from Bristol Myers Squibb, Roche-Genentech, Pfizer,Sanofi, and received travel support from Pfizer. A C J Akkooi: Amgen, Bristol-Myers Squibb, Novartis, MSD-Merck, Merck-Pfizer, Pierre Fabre,Provectus, Sanofi, Sirius Medical, 4SC (advisory board) and received research grants from Amgen andMerck-PfizerAll other authors declare no competing interests (M van Leeuwen, I Fraterman, N M J van denHeuvel, A H Boekhout, J Lai-Kwon, E A Wilthagen, L V van de Poll-Franse).

Publication types

MeSH terms

Substances

LinkOut - more resources